Abstract Highlights Pain Reduction for Patients

  • Friday, May 14, 2021

An abstract presented at the American Academy of Neurology's April virtual annual meeting titled “Reduction in Pain During and Between Attacks in Patients with Acute Hepatic Porphyria Treated with Givosiran: A Post-Hoc Analysis of the Phase 3 ENVISION Study” highlighted trial results from the Phase 3 Trial results of patients with acute porphyria taking GIVLAARI®. The results found that after six months patients found reduced pain during and in between acute attacks.

GIVLAARI® (givosiran) is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults.


Click Here to View the Abstract